All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

The role of consolidation after autologous stem cell transplantation

Jul 20, 2022
Learning objective: After listening to this discussion, learners will be able to cite the current recommendations and practice for consolidation therapy.

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria Mateos, Nina Shah, Paul Richardson, and Elena Zamagni. The topic of this discussion was “The role of consolidation after autologous stem cell transplantation”, which was identified as an unmet educational need within multiple myeloma treatment.


The role of consolidation after autologous stem cell transplantation

Gertz begins the discussion by explaining that patients often have confusion over what consolidation therapy is and when it can be used. Mateos then discusses how the number of induction therapy cycles a patient receives can affect the use of consolidation. Richardson talks about the STAMINA trial and how tolerability posttransplant can affect treatment choices, with Shah commenting on the difficulty of replicating trials in the real-world setting. The committee then discuss how historically in trials, the same drug that was used in induction is used as consolidation, and what the potential results would be if a different drug was used for consolidation.


The role of consolidation after autologous stem cell transplantation


Subscribe to get the best content related to multiple myeloma delivered to your inbox